Cytokinetics develops medicines that act on muscle function, starting with MYQORZO for obstructive hypertrophic cardiomyopathy, a serious heart disease. It last closed at $50.78 on Nov 20, down 1.32% on the day. The next earnings report for CYTK is expected around Tue, Feb 23, 2027, after the close. For the quarter ended Sep 2026, CYTK reported EPS of -$1.37 on revenue of $47.6M, with revenue up 2356.5% from a year ago. Over its last 8 reports the stock moved an average of 5.3% the session after earnings. Over the last 12 months CYTK insiders bought $0 of stock on the open market and sold $52.9M, according to SEC Form 4 filings.
AI Auto Pilots
Is CYTK in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CYTK.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on CYTKStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
CYTK · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 13% below its 20 day and 22% below its 50 day average. It is 37% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $50.32, and the nearest resistance the Pivot at $51.61.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 5.2%/day
Key levels
$88.3152 week high+73.9%
$70.11100 day average+38.1%
$69.49200 day average+36.8%
$61.8950 day average+21.9%
$59.08Swing high (Nov 11)+16.3%
$57.3820 day average+13.0%
$52.62Pivot R1+3.6%
$51.61Pivot+1.6%
$50.78Last close
$50.3252 week low−0.9%
$49.77Pivot S1−2.0%
Indicators
RSI (14)
29.60
Oversold below 30
Oversold
MACD
-3.24
Below its signal line
Bearish
Stochastic
4.4
Near the bottom of its range
Oversold
ADX (14)
29.9
Trending down
Williams %R
-96.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-105.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−5.4%
Change over 10 sessions
Bearish
ATR (14)
$2.62
Typical daily range, 5.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityNormal, 11.6%/day
Key levels
$88.3152 week high+73.9%
$70.11100 day average+38.1%
$69.49200 day average+36.8%
$61.8950 day average+21.9%
$59.08Swing high (Nov 11)+16.3%
$57.3820 day average+13.0%
$52.62Pivot R1+3.6%
$51.61Pivot+1.6%
$50.78Last close
$50.3252 week low−0.9%
$49.77Pivot S1−2.0%
Indicators
RSI (14)
30.83
Weak, oversold below 30
Neutral
MACD
-4.28
Below its signal line
Bearish
Stochastic
4.0
Near the bottom of its range
Oversold
ADX (14)
24.7
Weak trend
Williams %R
-98.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-147.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−31.2%
Change over 10 sessions
Bearish
ATR (14)
$5.91
Typical daily range, 11.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CYTK
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CYTK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow CYTK usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for CYTKHow many large options trades hit CYTK, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in CYTK in the last 90 days.
From SEC Form 4 filings by CYTK's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CYTK is in one of them and how their past CYTK trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Cytokinetics
Cytokinetics is a biopharmaceutical company based in South San Francisco, California, that develops medicines aimed at muscle function. Its first approved product is MYQORZO, a tablet for adults with obstructive hypertrophic cardiomyopathy, a serious heart disease. The company sells its medicines to patients and to prescribing cardiologists, and it is working on other drug candidates for heart and neuromuscular diseases.